Bayer’s Finerenone hits target in Phase III FIDELIO-DKD renal outcomes study
The company claims that finerenone is the first investigational non-steroidal, selective mineralocorticoid receptor antagonist to…
Recover your password.
A password will be e-mailed to you.
- Advertisement -
Recover your password.
A password will be e-mailed to you.